Hodgkin Lymphoma
Showing NaN - NaN of 17
Ovarian Reserve in Younger Newly Diagnosed Lymphomas
Active, not recruiting
- Anaplastic Large Cell Lymphoma
- +4 more
- Laboratory Biomarker Analysis
- Questionnaire Administration
-
Birmingham, Alabama
- +106 more
Jan 11, 2023
Hodgkin Lymphoma Trial in Worldwide (brentuximab vedotin, doxorubicin, vinblastine)
Active, not recruiting
- Hodgkin Lymphoma
- brentuximab vedotin
- +5 more
-
Fountain Valley, California
- +75 more
Dec 2, 2022
Participated in Children's Oncology Group Studies
Recruiting
- Acute Lymphoblastic Leukemia
- +5 more
- Assessment of Therapy Complications
- Questionnaire Administration
-
Birmingham, Alabama
- +163 more
Sep 6, 2022
Hodgkin Lymphoma, Non Hodgkin Lymphoma Trial in United States (AB-205, Placebo)
Recruiting
- Hodgkin Lymphoma
- Non Hodgkin Lymphoma
- AB-205
- Placebo
-
Duarte, California
- +20 more
Aug 2, 2022
Hematologic Malignancy, AML, ALL Trial in Australia, United States (Tagraxofusp, Fludarabine, Cytarabine)
Not yet recruiting
- Hematologic Malignancy
- +10 more
- Tagraxofusp
- +8 more
-
Los Angeles, California
- +28 more
Jul 26, 2022
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +12 more
- Laboratory Biomarker Analysis
- +2 more
-
Duarte, California
- +2 more
Feb 17, 2022
Acute Lymphocytic Leukemia, Acute Myelogenous Leukemia, Burkitt's Lymphoma Trial in United States (Haploidentical Bone Marrow
Completed
- Acute Lymphocytic Leukemia
- +6 more
- Haploidentical Bone Marrow Transplant
- Double Umbilical Cord Blood Transplant
-
Birmingham, Alabama
- +38 more
Nov 2, 2021
Hodgkin Lymphoma Trial in United States (brentuximab vedotin, nivolumab)
GVHD, AML, ALL Trial in Boston (FLUDARABINE, CYCLOPHOSPHAMIDE, TBI)
Recruiting
- GVHD
- +15 more
- FLUDARABINE
- +6 more
-
Boston, MassachusettsMassachusetts General Hospital
Sep 30, 2021
Hodgkin Lymphoma Trial in Boston (Brentuximab Vedotin, Adriamycin, Dacarbazine)
Completed
- Hodgkin Lymphoma
- Brentuximab Vedotin
- +2 more
-
Boston, Massachusetts
- +1 more
Aug 10, 2020
Lymphoid Malignancies, Multiple Myeloma, Lymphoma Trial in Boston, New York (Pralatrexate, Romidepsin)
Unknown status
- Lymphoid Malignancies
- +4 more
-
Boston, Massachusetts
- +1 more
Feb 6, 2020
Non-hodgkin Lymphoma, Hodgkin Lymphoma Trial in United States (Sirolimus, Methotrexate, Tacrolimus)
Completed
- Non-hodgkin Lymphoma
- Hodgkin Lymphoma
- Sirolimus
- +4 more
-
Atlanta, Georgia
- +4 more
Jan 30, 2019
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid
Withdrawn
- Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- +11 more
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine
- +2 more
-
Duarte, California
- +2 more
Nov 19, 2018
Hodgkin Lymphoma Trial in Tampa, Boston (Brentuximab Vedotin, Adriamycin, vinblastine, and dacarbazine)
Completed
- Hodgkin Lymphoma
- Brentuximab Vedotin
- Adriamycin, vinblastine, and dacarbazine
-
Tampa, Florida
- +3 more
Jan 23, 2018
Hodgkin Lymphoma Trial in Boston (Avastin)
Terminated
- Hodgkin Lymphoma
-
Boston, MassachusettsMassachusetts General Hospital
Sep 18, 2017
Hodgkin Lymphoma Trial in United States (Everolimus (RAD001))
Completed
- Hodgkin Lymphoma
- Everolimus (RAD001)
-
Los Angeles, California
- +15 more
Apr 18, 2016